SPONSORS of combined hormonal contraceptives (CHCs) are in the process of updating Product Information and Consumer Medicine Information for the products, after the TGA completed a review of the risk of blood clot disorders in women taking them.
The review found that for women who are using one of the contraceptives available in Australia the risk of a blood clot is increased but is still rare, with the increase in risk varying according to the progestogen included in the CHC.
Full details of the review and associated advice are at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Dec 16
